3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
87
Breast Neoplasms
49
Prostatic Neoplasms
42
Squamous Cell Carcinoma of Head and Neck
34
Lung Neoplasms
24
Neoplasms
19
Stomach Neoplasms
18
Head and Neck Neoplasms
17
Neoplasm Metastasis
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Urinary Bladder Neoplasms
13
Carcinoma, Transitional Cell
11
Triple Negative Breast Neoplasms
10
Ovarian Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Squamous Cell
8
Adenocarcinoma
8
HER2-positive Breast Cancer
7
Non-Muscle Invasive Bladder Neoplasms
6
Melanoma
6
Carcinoma
6
Small Cell Lung Carcinoma
5
Prostatic Neoplasms, Castration-Resistant
5
Nasopharyngeal Carcinoma
5
Esophageal Neoplasms
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Fallopian Tube Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Docetaxel
×
1 year
×
Clear all
NCT04060628
2026-01-23
Expanded Access to NanoDoce
NanOlogy, LLC
No longer available